About 5-hydroxytryptamine receptor 6
5-hydroxytryptamine receptor 6 (HTR6) is a protein
from Homo sapiens identified by UniProt accession
P50406, 440 residues long.
MolForge cross-references it against 0 known binders and
85 disease associations.
Target properties
| Protein name | 5-hydroxytryptamine receptor 6 |
| UniProt accession | P50406 |
| Gene | HTR6 |
| Organism | Homo sapiens |
| Length | 440 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (85)
Diseases linked to this target (Open Targets).
- schizophrenia · score 0.61
- schizoaffective disorder · score 0.50
- post operative nausea and vomiting · score 0.47
- depressive disorder · score 0.43
- Alzheimer disease · score 0.39
- psychosis · score 0.38
- unipolar depression · score 0.37
- mental or behavioural disorder · score 0.37
- obesity · score 0.37
- Nausea and vomiting · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P50406-F1 | alphafold | PREDICTED | 72.65 | — |
Amino-acid sequence (440 residues)
MVPEPGPTAN STPAWGAGPP SAPGGSGWVA AALCVVIALT AAANSLLIAL ICTQPALRNT SNFFLVSLFT SDLMVGLVVM PPAMLNALYG RWVLARGLCL LWTAFDVMCC SASILNLCLI SLDRYLLILS PLRYKLRMTP LRALALVLGA WSLAALASFL PLLLGWHELG HARPPVPGQC RLLASLPFVL VASGLTFFLP SGAICFTYCR ILLAARKQAV QVASLTTGMA SQASETLQVP RTPRPGVESA DSRRLATKHS RKALKASLTL GILLGMFFVT WLPFFVANIV QAVCDCISPG LFDVLTWLGY CNSTMNPIIY PLFMRDFKRA LGRFLPCPRC PRERQASLAS PSLRTSHSGP RPGLSLQQVL PLPLPPDSDS DSDAGSGGSS GLRLTAQLLL PGEATQDPPL PTRAAAAVNF FNIDPAEPEL RPHPLGIPTN
Explore 5-hydroxytryptamine receptor 6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets